首页> 外文期刊>The annals of pharmacotherapy >Author’s Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

【24h】

Author’s Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

机译：作者的回复：评论：将指南转化为实践：解释2016年ACC专家共识决定途径，即非他汀类疗法在动脉粥样硬化疾病风险管理中降低LDL胆固醇的作用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The annals of pharmacotherapy》 |2018年第1期|共2页
作者
Laura H. Waite; Yvonne L. Phan; Sarah A. Spinler;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献

1. Author’s Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk [J] . Laura H. Waite, Yvonne L. Phan, Sarah A. Spinler The annals of pharmacotherapy . 2018,第1期

机译：作者的回复：评论：将指南转化为实践：解释2016年ACC专家共识决定途径，即非他汀类疗法在动脉粥样硬化疾病风险管理中降低LDL胆固醇的作用
2. Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk [J] . Michelle Steicke, Yutang Wang The annals of pharmacotherapy . 2018,第1期

机译：评论：将指南转化为实践：解释2016年ACC专家共识决策途径，对非他汀类药物对动脉粥样硬化性心血管疾病风险的影响降低的非他汀类药物疗法的作用
3. Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk [J] . Waite Laura H., Phan Yvonne L., Spinler Sarah A. The annals of pharmacotherapy . 2017,第10期

机译：将指南转化为实践：解释2016年ACC专家共识决策途径，以非他汀类药物治疗在动脉粥样硬化疾病风险管理中降低的LDL-Cholesterol的作用
4. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery [O] . Glenn N. Levine, Eric R. Bates, John A. Bittl, 2016

机译：2016年ACC / AHA指南重点是冠心病患者双抗血小板治疗持续时间的重点：美国心脏病学 - 美国心脏病学院/美国心脏关联工作队的报告临床实践指南：2011年ACCF / AHA / SCAI指南的更新对于经皮冠状动脉干预，2011年冠状动脉旁路接枝外科手术，2012年ACC / AHA / ACP / AATS / PCNA / SCAI / STS指南诊断和管理稳定缺血性心脏病患者，2013年ACCF / AHA指南对于管理ST升高的心肌梗死，2014年AHA / ACC治疗非ST-EXTIVATION急性冠状动脉综合征的患者，2014年ACC / AHA指南围手术期心血管评估和管理患者患者患者

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号